Risperidone in children with disruptive behavior disorders: A 2-year open-label trial

被引：0
|
作者：
Reyes-Harde, M
Croonenberghs, J
Eerdekens, M
机构：
[1] Univ Antwerp, AZ Middelheim, Ctr Child & Adolescent Psychiat, B-2020 Antwerp, Belgium
[2] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80315-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S274 / S274
页数：1
相关论文
共 50 条
  • [31] Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study
    Rosenfeld, PJ
    Saperstein, DA
    Bressler, NM
    Reaves, TA
    Sickenberg, M
    Rosa, RH
    Sternberg, P
    Aaberg, TM
    Aaberg, TM
    OPHTHALMOLOGY, 2004, 111 (09) : 1725 - 1733
  • [32] Reduced Cutaneous Squamous Cell Carcinoma after Conversion to Sirolimus: A 2-Year Prospective Open-Label Multicenter Trial
    De Fijter, J. W.
    Hoogendijk-Van den Akker, J. M.
    Harden, P. N.
    Hoitsma, A. J.
    Proby, C.
    Wolterbeek, R.
    Bavinck, J. N. Bouwes
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 161 - 161
  • [33] Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study
    Fernandez, Hubert H.
    Stamler, David
    Davis, Mat D.
    Factor, Stewart A.
    Hauser, Robert A.
    Jimenez-Shahed, Joohi
    Ondo, William G.
    Jarskog, L. Fredrik
    Woods, Scott W.
    LeDoux, Mark S.
    Shprecher, David R.
    Anderson, Karen E.
    NEUROLOGY, 2018, 90
  • [34] Psychiataric symptoms among outpatients in an open-label trial of risperidone for methamphetamine dependence
    Jaffe, C
    Saxon, AJ
    Meredith, CW
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S146 - S146
  • [35] Efficacy of risperidone in children with disruptive behavioural disorders
    Duhig, Michael J.
    Saha, Sukanta
    Scott, James G.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2013, 49 (01) : 19 - 26
  • [36] An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder
    Hirschfeld, RMA
    Eerdekens, M
    Kalali, AH
    Canuso, CM
    Khan, AA
    Karcher, K
    Palumbo, JM
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (01) : 11 - 20
  • [37] Open-label risperidone in dementia with agitation/psychosis
    Prado, N
    KramerGinsberg, E
    Kremen, N
    Hanan, P
    Greenwald, BS
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1996, 4 (04): : 376 - 376
  • [38] Risperidone Treatment in Preschool Children with Disruptive Behavior Disorders: A Chart Review Study
    Coskun, Murat
    Zoroglu, Suleyman Salih
    Ozturk, Mucahit
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 21 (01): : 33 - 41
  • [39] Effect of lurasidone on cognition in children and adolescents with bipolar depression: Interim analysis of a 2-year open-label extension study
    Burdick, K. E.
    Goldman, R.
    Tocco, M.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S367 - S368
  • [40] Efficacy and safety of lurasidone in children and adolescents with bipolar depression: Results from a 2-year open-label extension study
    DelBello, M. P.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S236 - S236
12345